Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle and vasodilation, which can alleviate the symptoms of PAH.
Several examples of PGI2 analogs are currently in use, each with unique properties. Epoprostenol (Flotan), for instance, is delivered through a continuous intravenous infusion due to its short half-life. This means it must be administered continuously to maintain its therapeutic effect.
Treprostinil offers more versatility in terms of administration routes. It can be given via continuous intravenous and subcutaneous infusion, inhalation, or oral delivery. This flexibility can make it a more convenient option for some patients.
Iloprost (Ventavis), on the other hand, is available as an inhaled formulation. It has shown potent effects on relaxing pulmonary circulation, making it a valuable tool in the fight against PAH.
Beraprost was the first orally available PGI2 analog. However, despite its groundbreaking delivery method, it showed no significant benefit in long-term trials.
Selexipag (Uptravi) stands out as an orally active, selective IPR agonist. It boasts a rapid absorption rate and a longer half-life than other options, making it a practical choice for many patients.
As with any medication, prostacyclin receptor agonists come with potential adverse effects. Some patients may experience myalgias, extremity pain, jaw pain, nausea, headaches, abdominal discomfort, diarrhea, flushing, dizziness, systemic hypotension, and cough.
Prostacyclin receptor agonists are vital in managing pulmonary arterial hypertension.
They mimic prostaglandin I2 and bind to its receptor, IPR, on the smooth muscle cells. This triggers the adenylyl cyclase pathway, ultimately leading to smooth muscle relaxation and vasodilation.
Notable prostacyclin receptor agonists include epoprostenol, treprostinil, iloprost, beraprost, and selexipag.
Epoprostenol is administered via continuous intravenous infusion and has a short half-life.
Treprostinil can be administered via multiple routes, including continuous intravenous and subcutaneous infusions, inhalation, and oral.
Iloprost, available as an inhaled formulation, causes vasodilation in the lung's circulatory system.
Beraprost, the first orally available prostaglandin I2 analog, showed no benefit during long-term trials.
Selexipag, a selective IPR agonist, is rapidly absorbed and has a longer half-life.
Possible adverse effects of these agonists include musculoskeletal pain, headaches, abdominal discomfort, and systemic hypotension.
繁體中文
